Doxepin is NOT a Controlled Substance
Doxepin is not classified as a controlled substance under the federal Controlled Substances Act. Unlike benzodiazepines and other sedative-hypnotics used for insomnia, doxepin does not carry a DEA schedule designation 1, 2.
Regulatory Classification
The FDA drug labeling for doxepin makes no mention of controlled substance scheduling 2. This stands in stark contrast to the benzodiazepine receptor agonists (BzRAs) used for insomnia, which are explicitly designated as Schedule IV controlled substances 1.
Clinical Context
Multiple clinical guidelines consistently distinguish doxepin from controlled substances when discussing insomnia treatment:
Insomnia guidelines specifically note that sedating antidepressants like doxepin, amitriptyline, mirtazapine, and trazodone are "not FDA approved for insomnia" but are employed at lower-than-antidepressant doses for sleep 1
These same guidelines clearly label benzodiazepines and non-benzodiazepine hypnotics (zolpidem, eszopiclone, zaleplon) as "Schedule IV Controlled Substances," while making no such designation for doxepin 1
A 2025 research analysis explicitly states: "Most pharmacologic treatments with clinical data for insomnia symptoms are controlled substances. An exception is doxepin, an antihistamine that has shown efficacy for the treatment of difficulties with sleep maintenance" 3
Prescribing Implications
Because doxepin is not a controlled substance, prescribers do not need:
- DEA registration or special waivers to prescribe it
- To follow quantity limitations or refill restrictions mandated for controlled substances
- To report prescriptions to state prescription drug monitoring programs (PDMPs) as required for scheduled medications 4
This non-controlled status makes doxepin a particularly useful option for patients with insomnia who have substance use concerns or when prescribers wish to avoid controlled substances.